About Dr. Ogbede

Joseph joined the lab in fall of 2022. He has received his Bachelor's degree in Biochemistry from the Federal University of Technology, Owerri in Nigeria and his Master's in Medical Genetics and Genomics from the University of Glasgow, Scotland. His PhD is in Genome Science and Technology from the University of British Columbia, Canada. It was during his research there that he discovered the involvement of arginine biosynthetic pathway in the mechanism of toxicity of N-nitrosamines (a class of drug contaminants). Here at BCH, his work is focused on angiogenesis and cancer. He is currently investigating angiopoietin-TIE2 signaling to identify TIE2 agonists. He has used a phage display library containing phage clones expressing approximately one billion unique structurally constrained peptides and identified new small cyclic peptides that bind strongly to TIE2. These peptides are being studied in vitro and in vivo to understand their specific action.  In addition to the TIE2 project, Joseph is researching mRNA-based gene therapy in multiple myeloma. This project seeks to overcome resistance against immunomodulatory imide drugs (IMiDs) in multiple myeloma cells through mRNA restoration of cereblon.